Ligand Pharmaceuticals Incorporated
NASDAQLGND short interest surges 29% over one week to 12.03% of float, highest level in recent months as bearish positioning accelerates.
Ligand Pharmaceuticals reports Q2 results today with an unusually sharp shift in options positioning that stands out against an otherwise moderately bearish short-interest backdrop. The most striking pre-earnings…
LGND enters the back half of July with a notable reversal: the short squeeze that never quite came is now unwinding, even as analysts scramble to lift targets toward a stock price they've spent months chasing. The most…
Snapshot as of 16 Sept 2026
LGND heads into the week at $319.43 with a striking split: the Street just raised its price target to a 52-week high while short sellers have quietly doubled their position over the past month. The tension between…
Ligand Pharmaceuticals heads into the final weeks of Q2 with a sharp tension at its centre: the stock is up 20% in a month, directors are cashing out in size, and shorts are quietly rebuilding. The insider selling is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LGND — free to start on ORTEX.
Sign up for free →Open LGND on ORTEX